Last reviewed · How we verify

NCT06994221

Fibrosis Assessment in Myocardial Infarction-associated Ventricular Aneurysm

Recruiting now Last updated 29 May 2025
What this trial tests

trial testing 18F FAPI-42 PET/CT scan in Acute Myocardial Infarction in 20 participants. Currently enrolling.

Timeline
1 November 2024
Primary endpoint
31 July 2025
31 December 2025

Quick facts

Lead sponsorRenJi Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment20
Start date1 November 2024
Primary completion31 July 2025
Estimated completion31 December 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

RenJi Hospital

Who can join

Adults 18 to 75, any sex, with Acute Myocardial Infarction or Ventricular Aneurysm Following Acute Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will use 18F-FAPI PET/CT to study myocardial fibrosis in patients diagnosed with myocardial infarction-associated ventricular aneurysm (MI-VA). Participants will receive the PET/CT scan during hospital stay, as well as serial echocardiography and telephonic follow-ups. Analysed will focus on the characterization of myocardial fibrosis and its correlations with the clinical prognosis in the patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Myocardial Infarction

Currently open trials in the same condition.

Other RenJi Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06994221.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing